STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

NCT05519527 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 patient accrual

Conditions

Refractory T Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia (AML)

Interventions

DRUG: Part 1 (STI-6129)
DRUG: Part 2 (STI-6129)

Sponsor

M.D. Anderson Cancer Center